⚠️ This provider averages 845 services per working day — physically unusual for an individual practitioner
Based on 1.3M total services over 6 years (250 working days/year). Learn about impossible service volumes →
This provider's $10.2M in total Medicare payments ranks in the 99th percentile of Medical Oncology providers nationally.
Averaging 845 services per working day raises questions about billing patterns.
Medicare payments to this provider grew 10991% from 2018 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 1979% in 2020
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2018 | $286.63 | $71.40 | 4.01x | $215.23 | $31.8K | 446 | 7 |
| 2019 | $255.73 | $62.02 | 4.12x | $193.71 | $58.0K | 936 | 12 |
| 2020 | $19.09 | $5.90 | 3.24x | $13.19 | $1.2M | 204.5K | 45 |
| 2021 | $17.99 | $5.56 | 3.24x | $12.43 | $1.7M | 306.6K | 52 |
| 2022 | $27.78 | $9.99 | 2.78x | $17.79 | $3.7M | 368.9K | 56 |
| 2023 | $27.04 | $9.16 | 2.95x | $17.88 | $3.5M | 385.7K | 55 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | 104.5K | $1.8M | $16.98 | 2.48x |
| J9271 | Injection, pembrolizumab, 1 mg | 34.2K | $1.5M | $42.41 | 2.41x |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 35.1K | $1.3M | $36.97 | 2.70x |
| J9173 | Injection, durvalumab, 10 mg | 15.6K | $963.5K | $61.76 | 2.59x |
| Q5120 | Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg | 2.3K | $491.9K | $210.05 | 2.12x |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 5.2K | $460.1K | $88.88 | 2.67x |
| J9299 | Injection, nivolumab, 1 mg | 18.8K | $437.6K | $23.23 | 2.44x |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 450.8K | $399.4K | $0.89 | 2.81x |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 3.5K | $345.0K | $99.80 | 6.28x |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 129.5K | $338.5K | $2.62 | 3.03x |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | 1.6K | $210.8K | $130.14 | 2.19x |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 1.2K | $169.4K | $144.65 | 3.11x |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 4.2K | $143.6K | $34.18 | 4.31x |
| 74177 | Ct scan of abdomen and pelvis with contrast | 527 | $124.8K | $236.82 | 2.66x |
| J3590 | Unclassified biologics | 40 | $123.0K | $3.1K | 1.79x |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 4.5K | $114.6K | $25.46 | 1.92x |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 5.0K | $112.2K | $22.49 | 4.45x |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | 719 | $111.4K | $154.88 | 3.31x |
| 80053 | Blood test, comprehensive group of blood chemicals | 8.6K | $89.9K | $10.40 | 5.97x |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | 1.5K | $84.1K | $55.83 | 2.92x |
This provider submits charges 2.98 times higher than what Medicare actually pays.
A markup ratio of 2.98x means for every $100 Medicare pays, this provider initially charges $298. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data